SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences - Quaterly Results

20 May 2026 Evaluate
A decrease of about -35.72% in the sales to Rs. 37409.00 millions was observed for the quarter ended March 2026. The sales stood at Rs. 58196.00 millions during the similar quarter previous year.Profit after Tax for the quarter ended March 2026 saw a decline of -38.80% from Rs. 28137.00 millions to Rs. 17220.00  millions.The company reported a degrowth in operating Profit to 24842.00 millions from 39581.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 37409.00 58196.00 -35.72 114840.00 151163.00 -24.03 114840.00 151163.00 -24.03
Other Income 11430.00 1854.00 516.50 28962.00 9058.00 219.74 28962.00 9058.00 219.74
PBIDT 24842.00 39581.00 -37.24 55929.00 84325.00 -33.67 55929.00 84325.00 -33.67
Interest 1155.00 1554.00 -25.68 4829.00 4639.00 4.10 4829.00 4639.00 4.10
PBDT 22619.00 38027.00 -40.52 49431.00 79686.00 -37.97 49431.00 79686.00 -37.97
Depreciation 1509.00 1280.00 17.89 5612.00 5239.00 7.12 5612.00 5239.00 7.12
PBT 21110.00 36747.00 -42.55 43819.00 74447.00 -41.14 43819.00 74447.00 -41.14
TAX 3890.00 8610.00 -54.82 8221.00 16698.00 -50.77 8221.00 16698.00 -50.77
Deferred Tax -577.00 345.00 -267.25 -777.00 873.00 -189.00 -777.00 873.00 -189.00
PAT 17220.00 28137.00 -38.80 35598.00 57749.00 -38.36 35598.00 57749.00 -38.36
Equity 1006.00 1006.00 0.00 1006.00 1006.00 0.00 1006.00 1006.00 0.00
PBIDTM(%) 66.41 68.01 -2.36 48.70 55.78 -12.70 48.70 55.78 -12.70

Zydus Lifesciences Share Price

1085.45 9.00 (0.84%)
04-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.35
Dr. Reddys Lab 1267.05
Cipla 1397.75
Zydus Lifesciences 1085.45
Lupin 2248.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×